1620-72-0|2-Methyl-6-(trifluoromethyl)pyridine| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1620-72-0 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1620-72-0 ]

CAS No. :	1620-72-0
Formula :	C₇H₆F₃N
M.W :	161.12
SMILES Code :	CC1=NC(=CC=C1)C(F)(F)F
MDL No. :	MFCD07774130
InChI Key :	UTGYDHHZGXOFMZ-UHFFFAOYSA-N
Pubchem ID :	14761452

Safety of [ 1620-72-0 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P301+P312-P302+P352-P304+P340-P305+P351+P338

Computational Chemistry of [ 1620-72-0 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.29
Num. rotatable bonds	1
Num. H-bond acceptors	4.0
Num. H-bond donors	0.0
Molar Refractivity	34.2
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	12.89 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.8
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.17
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.56
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.91
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.79
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.45

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.54
Solubility	0.461 mg/ml ; 0.00286 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.07
Solubility	1.36 mg/ml ; 0.00844 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.29
Solubility	0.0832 mg/ml ; 0.000516 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.74 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.31

Application In Synthesis of [ 1620-72-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1620-72-0 ]

[ 1620-72-0 ] Synthesis Path-Downstream 1~35

1
[ 1574-41-0 ]
[ 353-85-5 ]
[ 1620-72-0 ]

References: [1]Journal of Organic Chemistry,1958,vol. 23,p. 765.
[2]Journal of Organic Chemistry,1958,vol. 23,p. 765.

2
[ 109-06-8 ]
[ 75-63-8 ]
[ 1620-72-0 ]
[ 31181-54-1 ]
[ 106877-17-2 ]
[ 106877-18-3 ]

References: [1]Journal of the Chemical Society. Perkin transactions I,1990,p. 2293 - 2299.

3
[ 109-06-8 ]
[ 75-63-8 ]
[ 1620-72-0 ]
[ 6140-17-6 ]
[ 401-79-6 ]
[ 13630-19-8 ]

References: [1]Journal of the Chemical Society. Perkin transactions I,1990,p. 2293 - 2299.

4
[ 5315-25-3 ]
[ 2314-97-8 ]
[ 1620-72-0 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

5
[ 1620-72-0 ]
[ 131747-42-7 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

6
[ 75-63-8 ]
[ 108-88-3 ]
[ 1620-72-0 ]
[ 6140-17-6 ]
[ 401-79-6 ]
[ 13630-19-8 ]

References: [1]Journal of the Chemical Society. Perkin transactions I,1990,p. 2293 - 2299.
[2]Journal of the Chemical Society. Perkin transactions I,1990,p. 2293 - 2299.

Yield	Reaction Conditions	Operation in experiment
2%		(4) 2-methyl-6-trifluoromethylpyridine; yield 2% deltaF -68 ppm (s) deltaH 2.63 ppm (3H, s) 7.4 ppm (1H, d, J:7.7 Hz) 7.52 ppm (1H, d, 7.7 Hz) 7.84 ppm (1H, t).

8
[ 1824-81-3 ]
[ 1620-72-0 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

9
[ 1620-72-0 ]
[ 131747-65-4 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

10
[ 1620-72-0 ]
[ 131747-53-0 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

11
[ 1620-72-0 ]
[ 131747-78-9 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

12
[ 1620-72-0 ]
[ 108337-80-0 ]

References: [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458.

13
[ 353-85-5 ]
[ 1620-72-0 ]

References: [1]Journal of Organic Chemistry,1958,vol. 23,p. 765.
[2]Gmelin Handbuch der Anorganischen Chemie,Gmelin Handbook: F: PerFHalOrg.9, 7, page 50 - 101.

14
[ 1620-72-0 ]
[ 1321515-80-3 ]

References: [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1898 - 1903.

15
[ 1620-72-0 ]
[ 73183-34-3 ]
[ 1321518-03-9 ]

Yield	Reaction Conditions	Operation in experiment
83%		In a two-neck flask, equipped with stirring bar, condenser and a rubber septum, thoroughly purged with argon, were introduced methoxy(cyclooctadiene)iridium(l) dimer (21 mg, 0.03 mmol), 4,4?-di-tert-butyl-2,2?-bipyridine (17 mg, 0.06 mmol), and bis(pinacolato)diboron (2.05 g, 8.1 mmol). The flask was once more purged before adding hexane via syringe (15 mL). The re5 suIting mixture was heated at 5000 for 10 mm until the appearance of a dark-red solution wasobserved. <strong>[1620-72-0]2-trifluoromethyl-6-methyl pyridine</strong> (2.0 g, 12.4 mmol) was then added by syringe, and heating continued for a further 6 h. After cooling to room temperature, the crude reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography, eluting with hexane/ethyl acetate mixture to afford the target compound2-(trifl uoromethyl)-4-(4,4,5,5-tetramethyl-1 ,3 ,2-d ioxaborolan-2-yl)-6-methylpyrid me (2.95 g,83%) as a light brown thick oil. ESI-MS: 206.20 [M+H]+ (boronic acid).
67.4%		Under a nitrogen atmosphere, (1,5-cyclooctadiene)methoxyindole(I) dimer (1.0 g, 1.55 mmol),4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolane) (15.7 g, 62.1 mmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (0.83 g, 3.1 mmol) were dissolved in 100 mL of n-hexane, heated to 50 C, and stirred for 10 minutes. <strong>[1620-72-0]2-methyl-6-(trifluoromethyl)pyridine</strong> 1a (5 g, 31 mmol, prepared by a known method "Chemical and Pharmaceutical Bulletin, 1990, 38(9), 2446-2458") was added, and the stirring reaction was continued. 4 hours. The reaction was stopped, cooled to room temperature, filtered, and the filtrate was concentrated.The residue was purified by thin layer chromatography using a developing solvent system B.The title compound 1b (6 g, yield: 67.4%) was obtained.

References: [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 1898 - 1903.
[2]Patent: WO2019/2606,2019,A1 .Location in patent: Page/Page column 77; 78.
[3]Patent: CN109535161,2019,A .Location in patent: Paragraph 0235; 0238-0242.

16
[ 1620-72-0 ]
[ 781637-62-5 ]

Yield	Reaction Conditions	Operation in experiment
28.4%	With N-Bromosuccinimide; 1,1'-azobis(1-cyanocyclohexanenitrile); In tetrachloromethane; at 90℃; for 15h;	<strong>[1620-72-0]2-methyl-6-(trifluoromethyl)pyridine</strong> (100 mg, 0.620 mmol) was dissolved in CC14 (3 mL), and N-bromosuccinimide (NBS) (110 mg, 0.620 mmol) and 1,1'- azobis(cyclohexanecarbonitrile) (VAZO, 8 mg, 0.031 mmol) were added thereto, followed by heating and stirring at 90 C for 15 hrs. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by MPLC (Hex/EA = 5:1) to obtain the title compound as white solid (42.5 mg, yield: 28.4%). 1H NMR (300MHz, CDC13) delta 4.60 (2H, s), 7.61 (1H, d), 7.68 (1H, d), 7.90 (1H, t)
28.4%	With N-Bromosuccinimide; 1,1'-azobis(1-cyanocyclohexanenitrile); In tetrachloromethane; at 90℃; for 15h;	<strong>[1620-72-0]2-methyl-6-(trifluoromethyl)pyridine</strong> (100 mg, 0.620 mmol) was dissolved in CCl4 (3 mL), and N-bromosuccinimide (NBS) (110 mg, 0.620 mmol) and 1,1'-azobis(cyclohexanecarbonitrile) (VAZO, 8 mg, 0.031 mmol) were added thereto, followed by heating and stirring at 90 C. for 15 hrs. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by MPLC (Hex/EA=5:1) to obtain the title compound as white solid (42.5 mg, yield: 28.4%). 1H NMR (300 MHz, CDCl3) delta 4.60 (2H, s), 7.61 (1H, d), 7.68 (1H, d), 7.90 (1H, t)

References: [1]Patent: WO2013/129879,2013,A1 .Location in patent: Page/Page column 50; 51.
[2]Patent: US2015/166558,2015,A1 .Location in patent: Paragraph 0300; 0301; 0302.

17
[ 5315-25-3 ]
[ 77152-08-0 ]
[ 1620-72-0 ]

References: [1]Journal of Organic Chemistry,2013,vol. 78,p. 11126 - 11146.

18
[ 5315-25-3 ]
(1,10-phenanthroline)(trifluoromethyl)copper(I) [ No CAS ]
[ 1620-72-0 ]

References: [1]Organic Letters,2014,vol. 16,p. 1744 - 1747.

19
[ 1620-72-0 ]
4-ethyl-2-methyl-6-(trifluoromethyl)pyridine-1-oxide [ No CAS ]